Green-top Guideline No. 8: Amniocentesis and Chorionic Villus Sampling

RCOG

This guideline sets a series of evidence-based standards to ensure a high level and consistency of practice in the provision and performance of amniocentesis and chorionic villus sampling (CVS). 1. Key recommendations (00:34) 2. Aim (02:17) 3. Background (02:52) 4. Identification and assessment of evidence (05:36) 5. How should care be organised in providing amniocentesis and CVS? (6:38) 6. What are the additional risks associated with invasive testing? (09:44) 6.1 What is the additional risk of miscarriage associated with amniocentesis and CVS? (09:51) 6.2 What are the additional risks associated with invasive testing? (23:19) 7. At what gestation should amniocentesis and CVS be carried out? (24:24) 7.1 At what gestation should amniocentesis be carried out? (24:32) 7.2 When should CVS be carried out? (27:24) 8. What are the considerations when performing amniocentesis or CVS for multiple pregnancy? (29:30) 9. What is the role of third trimester amniocentesis? (37:44) 10. What are the risks of mother to child transmission of infection? (40:33) 11. Recommendations for future research (47:24) 12. Auditable topics (47:44) 13. Useful links and support groups (48:57) Disclosures of interest (50:33) Funding (50:49) References (51:30)